EW|Edwards Lifesciences Corp|Preço:80.500|

Mais detalhes de Edwards Lifesciences Corp Empresa

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Informações de Edwards Lifesciences Corp



Código da empresaEW

Nome da EmpresaEdwards Lifesciences Corp

Data de listagemMar 27, 2000

CEOZovighian (Bernard J)

Número de funcionários15800

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 27

EndereçoOne Edwards Way

CidadeIRVINE

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal92614

Telefone19492502500

Sitehttps://www.edwards.com

Código da empresaEW

Data de listagemMar 27, 2000

CEOZovighian (Bernard J)

Executivos da empresa Edwards Lifesciences Corp



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+4682.00%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

--

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

17.91K

-2000.00%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+3528.00%

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Ms. Leslie S. Heisz

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+4682.00%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

--

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

17.91K

-2000.00%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+3528.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por EmpresaUSD

Nome

Receita

Proporção

Transcatheter Aortic Valve Replacement

1.15B

74.04%

Surgical Heart Valve Therapy

258.00M

16.61%

Transcatheter Mitral and Tricuspid Therapies

145.20M

9.35%

Por RegiãoUSD

Nome

Receita

Proporção

United States

907.50M

58.43%

Europe

387.90M

24.98%

Rest of the world

167.60M

10.79%

Japan

90.10M

5.80%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Transcatheter Aortic Valve Replacement

1.15B

74.04%

Surgical Heart Valve Therapy

258.00M

16.61%

Transcatheter Mitral and Tricuspid Therapies

145.20M

9.35%

Distribuição de ações

Atualizado em: sáb, 10 de jan

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

12.03%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

Outro

71.62%

Investidores

Proporção

The Vanguard Group, Inc.

12.03%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

Outro

71.62%

Tipos de investidores

Investidores

Proporção

Investment Advisor

46.83%

Investment Advisor/Hedge Fund

30.96%

Hedge Fund

3.47%

Pension Fund

2.27%

Research Firm

2.17%

Bank and Trust

1.96%

Sovereign Wealth Fund

1.37%

Individual Investor

0.93%

Endowment Fund

0.83%

Outro

9.21%

Participação acionária institucional



Atualizado em: seg, 8 de dez

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

2452

517.66M

93.53%

--

2025Q3

2537

517.80M

94.00%

-1.50M

2025Q2

2614

519.17M

94.35%

-5.19M

2025Q1

2599

525.51M

93.66%

-25.15M

2024Q4

2585

522.16M

89.45%

+17.15M

2024Q3

2546

504.88M

87.53%

-10.03M

2024Q2

2541

515.71M

87.77%

+1.93M

2024Q1

2555

513.21M

86.74%

-8.92M

2023Q4

2556

503.19M

87.55%

-12.35M

2023Q3

2509

516.79M

88.03%

-521.37K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

70.09M

12.08%

+359.01K

+0.51%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

30.52M

5.26%

-370.16K

-1.20%

Sep 30, 2025

State Street Investment Management (US)

25.62M

4.41%

-14.75K

-0.06%

Sep 30, 2025

Wellington Management Company, LLP

20.80M

3.59%

+977.93K

+4.93%

Sep 30, 2025

JP Morgan Asset Management

17.92M

3.09%

-2.17M

-10.80%

Sep 30, 2025

Jennison Associates LLC

13.96M

2.41%

+2.29M

+19.60%

Sep 30, 2025

Fidelity Management & Research Company LLC

13.03M

2.25%

+10.73M

+466.56%

Sep 30, 2025

Geode Capital Management, L.L.C.

12.84M

2.21%

+114.73K

+0.90%

Sep 30, 2025

Walter Scott & Partners Ltd.

9.96M

1.72%

+1.05M

+11.73%

Sep 30, 2025

Union Investment Privatfonds GmbH

8.60M

1.48%

+19.17K

+0.22%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

iShares U.S. Medical Devices ETF

4.72%

Future Fund Long/Short ETF

3.86%

iShares Health Innovation Active ETF

3.65%

Global X Aging Population ETF

3.31%

Acruence Active Hedge US Equity ETF

2.58%

First Trust Indxx Medical Devices ETF

2.23%

State Street SPDR S&P Health Care Equipment ETF

1.88%

JPMorgan Healthcare Leaders ETF

1.8%

PGIM Jennison Better Future ETF

1.78%

ROBO Global Healthcare Technology & Innovation ETF

1.73%

Ver Mais

iShares U.S. Medical Devices ETF

Proporção4.72%

Future Fund Long/Short ETF

Proporção3.86%

iShares Health Innovation Active ETF

Proporção3.65%

Global X Aging Population ETF

Proporção3.31%

Acruence Active Hedge US Equity ETF

Proporção2.58%

First Trust Indxx Medical Devices ETF

Proporção2.23%

State Street SPDR S&P Health Care Equipment ETF

Proporção1.88%

JPMorgan Healthcare Leaders ETF

Proporção1.8%

PGIM Jennison Better Future ETF

Proporção1.78%

ROBO Global Healthcare Technology & Innovation ETF

Proporção1.73%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

May 07, 2020

Split

1→3

Data

Data ex-dividendo

Tipo

Proporção

May 07, 2020

Split

1→3